Accendra Health
Distributor of home medical equipment and supplies, renamed from Owens & Minor.
On the record
Checkpoint: Q2 2026 earnings, key test of whether free cash flow turns positive again
The call
Accendra Health keeps its physical network and payor deals, but a lost $322M contract and 9%+ debt leave equity holders riding on a thin cash flow recovery.
Accendra Health delivers wheelchairs, oxygen tanks, and other medical equipment to patients through 300+ locations and relationships with insurance companies. The company is hard to replace because it has licenses, contracts with major insurers, and a physical footprint, but these advantages are weaker than they look: it just lost a customer worth 12% of sales, and bigger insurers like UnitedHealth are squeezing out smaller distributors or doing the work themselves. The real problem is debt. Accendra borrowed $1.75 billion at interest rates around 9% per year, but cash flow collapsed in early 2026, and the company's net worth is deeply negative. If cash flow does not recover sharply by mid-2026, the debt becomes impossible to refinance, and equity investors could lose everything in a restructuring.
Why
01
AI pressure: None apparent. AI mainly speeds up billing and eligibility checks here, it does not replace trucks, warehouses, or licensed DME delivery. Could AI do the core job? Unlikely.
02
Bigger players: UnitedHealth Group / Optum. Optum's preferred-partner network pulled a $322M payor contract, about 12% of sales, starting late 2025. Could a giant copy it? Probably.
03
What protects it. Payor contracts, state licensure, and over 300 physical locations still make Accendra hard to swap out quickly.
What would change this call
Q2/Q3 2026 operating cash flow reported around August 2026. Shows whether the cash flow deterioration reverses or the payor loss keeps hurting liquidity.
Any new large payor contract win or additional payor contract loss disclosed in 2026. Shows whether the payor relationship moat is holding or continuing to erode.
Compliance with covenants under the new 9.000%/9.750% notes and any refinancing news. Shows whether the debt load becomes unmanageable and threatens equity holders.
Any new large payor contract win or additional payor contract loss disclosed in 2026. Shows whether the payor relationship moat is holding or continuing to erode.
Compliance with covenants under the new 9.000%/9.750% notes and any refinancing news. Shows whether the debt load becomes unmanageable and threatens equity holders.
Key numbers
- Q1 2026 revenue $627.8M, down 6.8% y/y
- Stockholders' deficit $(465)M, BV/share $(6.07)
- New debt stack: 9.00%/9.75% notes, $1.75B total
Named risks
- Negative stockholders' equity of $(465)M and negative book value per share of $(6.07) as of Q1 2026.
- Q1 2026 operating cash flow turned negative at $(50)M versus $370M FCF in FY2025.
- High-coupon 9.00%-9.75% debt stack totaling $1.752B pro forma faces refinancing and covenant risk.
- Additional $40M revenue headwind expected in 2027 from same payor exit that cost $322M in 2026.
- Fitch withdrew credit ratings around March 13, 2026, reducing external credit visibility.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| UnitedHealth Group / Optum | contesting | Acts as preferred-partner gatekeeper for Apria/Byram DME network as of March 2026, also a vertical-integration threat |
| Unnamed large commercial payor | losing to | Terminated $322M annual contract (12% of sales), disclosed Feb 19, 2026, with $40M more headwind expected in 2027 |
| Rotech Healthcare | contesting | Planned $1.36B acquisition of Rotech collapsed June 2025 due to regulatory hurdles, $80M breakup fee paid |
| Lincare | contesting | Cited as comparable DME distribution competitor in home medical equipment space as of 2026 |
| Molina Healthcare | gaining on | Byram Healthcare named preferred DME provider covering 18 states and 4.5M covered lives |
Questions people ask
- Is Accendra Health profitable in 2026?
- Accendra Health guided FY2026 free cash flow of at least $100M and Adjusted EBITDA of $335M-$355M, but Q1 2026 operating cash flow was $(50)M, a reversal from $370M FCF in FY2025, as reported May 11, 2026, raising doubts about hitting guidance.
- Did Accendra Health used to be Owens & Minor?
- Yes. Owens & Minor, Inc. renamed itself Accendra Health, Inc. effective December 31, 2025, immediately after selling its Products & Healthcare Services segment and the Owens & Minor brand to Platinum Equity for $375 million cash.
- Is Accendra Health's debt sustainable?
- As of Q1 2026 Accendra carried a stockholders' deficit of about $(465)M and negative book value per share of $(6.07). In June 2026 it exchanged notes for 9.000% and 9.750% coupon debt, reducing funded debt from $2,123M to $1,752M pro forma, but the high coupons remain a strain.
- Who is Accendra Health's biggest competitor?
- Rotech Healthcare and Lincare are the closest DME distribution rivals, while UnitedHealth's Optum acts as both a preferred-partner gatekeeper (Apria/Byram joined its Preferred DME Network) and a vertical-integration threat, as of March 2026 reporting.
- Could AI replace Accendra Health's business?
- Not directly. Accendra's core moat is physical DME delivery, payor contracts, and Medicare/Medicaid licensure across 300+ locations, not software. AI is expected to automate back-office tasks like eligibility verification and billing QA, per industry analysis from June 2026, but not disintermediate physical distribution.
- What happened to Accendra Health's Rotech acquisition?
- Accendra Health (then Owens & Minor) terminated its $1.36 billion agreement to acquire Rotech Healthcare in June 2025 due to regulatory hurdles, paying an $80 million breakup fee, according to Wikipedia's June 13, 2026 update.
Timeline
- 2026-07-20Stock fell 8.2% to $3.47 after Q1 2026 operating cash flow turned negative
- 2026-06-23Debt exchange settled, reducing funded debt from $2,123M to $1,752M pro forma
- 2026-05-11Q1 2026 results: revenue $627.8M, operating cash flow $(50)M, deficit $(465)M
- 2026-03-13Fitch withdrew credit ratings on Accendra Health
- 2026-02-19Disclosed $322M payor contract loss and FY2026 guidance cut
- 2025-12-31Completed $375M sale of P&HS segment and Owens & Minor brand to Platinum Equity
- 2025-12-18Announced corporate rename from Owens & Minor to Accendra Health
- 2025-06-01Terminated $1.36B Rotech Healthcare acquisition, paid $80M breakup fee
Revision history
20 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Accendra's Margins Surge, But Revenue Still Slips (2026-07-13)
- Accendra's $300M Payer Hit Clouds 2026 Growth Outlook (2026-02-19)
- Owens & Minor Earnings 2025 Annual (2026-02-20)
- Accendra Health Plunges 8% as Cash Flow Turns Negative (2026-07-20)
- Accendra Health Q1 2026 press release (2026-05-11)
- Byram Healthcare profile (2026-03-12)
- Accendra Health (2026-06-13)
- National Preferred Provider for Molina Healthcare
- Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity (2025-12-31)
- Accendra Health Company Profile
- Accendra Health Reports Fourth Quarter 2025 Financial Results (2026-02-19)